Pemphigus is a rare, life-threatening, mucocutaneous, autoimmune blistering disease. Therapeutic options include long-term, high-dose corticosteroid therapy and steroid-sparing agents such as azathioprine, cyclophosphamide, methotrexate, and intravenous immunoglobulin. Rituximab is a chimeric murine-human monoclonal antibody targeting the CD20 antigen on B cells. In published studies of pemphigus, the dosing schedule for rituximab is similar to that indicated for non-Hodgkin B-cell lymphoma, namely 1 cycle of 4 weekly infusions at 375 mg/mm2 of body surface area. In this case series, Matsukura et al demonstrate that an alternative dosing regimen of 100 mg on days 1 and 15 was an effective treatment for pemphigus.